Serotonin Syndrome and NMS — Written Clinical Reasoning

SAQ 1 — Recognition and Management of Serotonin Syndrome (20 marks, 30 minutes)

Prompt: Outline your integrated management of this patient, including: (a) the diagnosis and the clinical reasoning that supports it; (b) the immediate pharmacological and supportive management with exact drugs, doses and rationale; (c) how you would distinguish this from neuroleptic malignant syndrome and anticholinergic toxicity; (d) the complications you must monitor for in the first 48 hours; and (e) the plan for her psychiatric medication once she recovers. [1]

Model Answer

(a) Diagnosis and clinical reasoning (4 marks): [1]

The diagnosis is serotonin syndrome, precipitated by the combination of three serotonergic agents — sertraline (an SSRI blocking serotonin reuptake), tramadol (also a serotonin reuptake inhibitor), and linezolid (a weak reversible monoamine oxidase inhibitor blocking serotonin metabolism) [1][8]. The addition of linezolid to her existing sertraline and tramadol created a multiplicative rise in synaptic serotonin. She fulfils the Hunter Serotonin Toxicity Criteria — recent serotonergic drug exposure plus inducible clonus with agitation and diaphoresis [2]. The clinical triad is present: neuromuscular hyperactivity (inducible and ocular clonus, lower-limb hyperreflexia, tremor), autonomic instability (hyperthermia, tachycardia, hypertension, mydriasis, diaphoresis), and altered mental status (agitation, confusion) [1]. The rapid onset within 18 hours of the drug interaction is characteristic; NMS evolves over days to weeks, not hours [5].

(b) Immediate management (6 marks): [1]

1. Stop all serotonergic agents immediately — cease sertraline, tramadol, and linezolid. Substitute linezolid with a non-serotonergic alternative for her MRSA osteomyelitis (vancomycin). Review all medications, over-the-counter agents (especially cough suppressants containing dextromethorphan), and herbal agents (St John's wort). [1]

2. Airway, breathing, circulation — high-flow oxygen; establish intravenous access; continuous cardiac monitoring for arrhythmia. Her airway is currently protected but she must be monitored closely for deterioration. [1]

3. Benzodiazepines as first-line — diazepam 5 to 10 mg intravenously, repeated every 5 to 10 minutes as required, titrated to control agitation and reduce muscle tone. Benzodiazepines enhance GABAergic inhibition, which indirectly reduces serotonergic tone, and by controlling agitation and rigidity they reduce the muscle-generated heat driving her hyperthermia [1]. Lorazepam 1 to 2 mg intravenously is an alternative.

4. Active cooling — remove clothing, evaporative cooling, fans, ice packs to groins and axillae. Antipyretics (paracetamol) will not work because the hyperthermia is muscle-generated, not prostaglandin-mediated. [1]

5. Intravenous fluids — isotonic crystalloid to maintain urine output and protect against rhabdomyolysis-induced acute kidney injury. Target urine output 1 to 2 mL/kg/hour. [1]

6. Cyproheptadine for moderate-to-severe disease — a 5-HT2A receptor antagonist. Initial dose 12 mg orally (via nasogastric tube if needed), then 2 mg every 2 hours until clinical response (maximum 32 mg in 24 hours), then maintenance 8 mg every 6 hours. Limitation: oral only, no intravenous formulation, evidence limited to case series [6].

7. Escalation if severe — if she develops temperature above 41 degrees, rigidity, seizures, or loss of airway reflexes, intubate and paralyse with a non-depolarising neuromuscular blocker (rocuronium 1.0 to 1.2 mg/kg for intubation). Avoid succinylcholine because of the risk of hyperkalaemia from rhabdomyolysis and theoretical malignant hyperthermia unmasking [1].

(c) Distinguishing from NMS and anticholinergic toxicity (4 marks): [1]

From NMS: NMS is caused by dopamine D2 blockade (antipsychotics) or dopamine withdrawal, with a gradual onset over days to weeks, lead-pipe rigidity (greater in the upper limbs), bradyreflexia (not hyperreflexia or clonus), and a markedly elevated creatine kinase (often into the thousands) [3][4]. This patient has hours of onset, clonus and hyperreflexia, a mild CK (480), and a clear serotonergic drug trigger — all pointing away from NMS [5].

From anticholinergic toxicity: anticholinergic toxicity produces dry skin and dry mucous membranes (anhidrosis), urinary retention, and decreased bowel sounds (ileus). This patient is diaphoretic with active bowel sounds and diarrhoea — the opposite pattern. Clonus is not a feature of anticholinergic toxicity. The mnemonic for anticholinergic toxicity ('dry as a bone, red as a beet, blind as a bat, mad as a hatter') contrasts with the wet, hyperkinetic picture of serotonin syndrome [6].

(d) Complications to monitor in the first 48 hours (3 marks): [1]

• Rhabdomyolysis and acute kidney injury — serial creatine kinase, creatinine, urine output. Treat with aggressive intravenous fluids; consider sodium bicarbonate if severe acidosis or myoglobinuria.
• DIC and coagulopathy — serial INR, APTT, fibrinogen, D-dimer, platelets.
• Arrhythmia — continuous cardiac monitoring; correct potassium, calcium, magnesium.
• Seizures — benzodiazepines; watch for non-convulsive status if mental status fails to improve.
• Aspiration — from reduced consciousness and agitation; consider early airway protection.
• Hepatic dysfunction — serial liver function tests. [1]

(e) Psychiatric medication plan after recovery (3 marks): [1]

The underlying depression must not be neglected. After full resolution of serotonin syndrome (typically 24 to 72 hours), serotonergic antidepressants can usually be re-introduced cautiously — a single agent at low dose, with careful monitoring, avoiding combinations and MAOIs [1]. The risk of recurrence with a single SSRI at standard dose is low. I would involve the consultation-liaison psychiatry team early to plan the re-challenge. Tramadol should be replaced with a non-serotonergic analgesic (e.g., oxycodone, paracetamol-based regimens). I would document the linezolid-serotonergic interaction as a drug allergy/adverse reaction in her medication record and warn her and her family about combining serotonergic agents in the future.

SAQ 2 — Parkinson Withdrawal-Emergent NMS (10 marks)

Prompt: A 74-year-old man with advanced Parkinson disease (on levodopa-carbidopa, entacapone, and amantadine) is admitted with a fractured neck of femur. His Parkinson medications are withheld perioperatively for three days due to nil-by-mouth status and swallowing difficulty. On day three he becomes confused and febrile (39.8 degrees), with marked lead-pipe rigidity (greater in the upper limbs), bradyreflexia, diaphoresis and a creatine kinase of 6200 U/L. Outline the diagnosis, the immediate management, and how you would prevent this complication. [1]

Model Answer

Diagnosis (3 marks): [1]

This is parkinsonism-hyperpyrexia syndrome (also called withdrawal-emergent neuroleptic malignant syndrome) — a syndrome clinically identical to NMS, produced by the abrupt withdrawal of dopaminergic therapy (levodopa-carbidopa, entacapone, amantadine) in a patient with Parkinson disease [3]. The clinical picture (hyperthermia, lead-pipe rigidity, altered mental status, bradyreflexia, markedly elevated CK) fulfils the NMS diagnostic framework, but the mechanism is dopamine deficiency rather than dopamine blockade [4].

Immediate management (4 marks): [1]

1. Reinstate the dopaminergic therapy urgently — the definitive treatment. Give levodopa-carbidopa via nasogastric tube if swallowing is impaired, and restart amantadine. This is the single most important intervention. Bromocriptine may be added as a dopamine agonist but is insufficient as monotherapy because it does not replace the levodopa the brain needs.
2. Supportive care — intravenous fluids for rhabdomyolysis (target urine output 1 to 2 mL/kg/hour), active cooling, correction of electrolytes (especially calcium and magnesium), DVT prophylaxis (she is immobile and at high risk), and monitoring for AKI and DIC.
3. Dantrolene (1 mg/kg intravenously, repeat to 10 mg/kg) for severe rigidity and hyperthermia, as an adjunct.
4. Treat the fracture in coordination with orthopaedics and anaesthetics; avoid dopamine-blocking antiemetics (metoclopramide, prochlorperazine) — use ondansetron if needed (noting its mild serotonergic activity). [1]

Prevention (3 marks): [1]

The complication is avoidable. Parkinson medications must not be withheld perioperatively [3]. Strategies: (1) continue levodopa via nasogastric tube if nil-by-mouth; (2) use dispersible levodopa formulations; (3) coordinate timing of surgery around medication schedule; (4) involve the neurology team at preadmission for any Parkinson patient facing surgery; (5) ensure all staff understand that withholding Parkinson medications is dangerous — the risk of withdrawal-emergent NMS far outweighs the logistical difficulty of continuing them. Document the plan clearly in the medication chart.